Latest Breaking News On - தடி லீட்ஸ் டேவிட் வால்ட்மேன் - Page 1 : comparemela.com

Scopus BioPharma Finalizes Arrangements for Submission of IND Package Submission to FDA Expected in Q2 2021 News provided by Share this article NEW YORK, March 15, 2021 /PRNewswire/  Scopus BioPharma Inc. (Nasdaq: SCPS ) today announced the finalization of arrangements for the completion of the investigational new drug ( IND ) package for the company s lead drug candidate and its submission to the United States Food and Drug Administration ( FDA ). The IND submission is expected in Q2 2021. Scopus is a biopharmaceutical company developing transformational therapeutics based on groundbreaking scientific and medical discoveries. The company s lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers.

United statesRodd leeds david waldmanScopus biopharmaJoshuar lamsteinExchange commissionScopus biopharma incCrescendo communicationsDrug administrationPrnewswire scopus biopharma incUnited states foodஒன்றுபட்டது மாநிலங்களில்தடி லீட்ஸ் டேவிட் வால்ட்மேன்பரிமாற்றம் தரகுபிறை தகவல்தொடர்புகள்ஒன்றுபட்டது மாநிலங்களில் உணவு